Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Orthocell Ltd ( (AU:OCC) ) has issued an announcement.
Orthocell Limited has issued 150,000 fully paid ordinary shares at $0.48 each following the exercise of unlisted options, complying with relevant sections of the Corporations Act 2001. This issuance reflects the company’s ongoing efforts to strengthen its financial position and support its operations in the regenerative medicine sector, potentially impacting its market presence and stakeholder interests.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company specializing in developing products for the repair of bone and soft tissue injuries. Their product portfolio includes collagen medical devices for tissue reconstruction in dental and orthopedic applications, with products like Striate+™ and Remplir™ cleared for use in multiple countries. The company is also advancing its tendon cell therapy in the US.
Average Trading Volume: 633,124
Technical Sentiment Signal: Buy
Current Market Cap: A$329.7M
For detailed information about OCC stock, go to TipRanks’ Stock Analysis page.